Published online before print January 23, 2006, doi: 10.1161/01.HYP.0000203309.07140.d3
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2006;47:352.)
© 2006 American Heart Association, Inc.
Original Articles |
Comparative Antihypertensive Effects of Hydrochlorothiazide and Chlorthalidone on Ambulatory and Office Blood Pressure
From the Division of Clinical and Administrative Pharmacy, College of Pharmacy (M.E.E., B.L.C., J.J.G.S., B.B.P.), Departments of Family Medicine (M.E.E., B.L.C., G.R.B.) and Internal Medicine (C.J.G.), Roy J. and Lucille A. Carver College of Medicine, and Department of Biostatistics, College of Public Health (M.B.Z.), University of Iowa; Pharmacy Department (J.J.G.S.), Veterans Affairs Medical Center; and Department of Pharmaceutical Care (B.B.P.), University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Correspondence to Michael E. Ernst, Department of Family Medicine/01291-A PFP, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA 52242. E-mail michael-ernst{at}uiowa.edu
Low-dose thiazide-type diuretics are recommended as initial therapy for most hypertensive patients. Chlorthalidone has significantly reduced stroke and cardiovascular end points in several landmark trials; however, hydrochlorothiazide remains favored in practice. Most clinicians assume that the drugs are interchangeable, but their antihypertensive effects at lower doses have not been directly compared. We conducted a randomized, single-blinded, 8-week active treatment, crossover study comparing chlorthalidone 12.5 mg/day (force-titrated to 25 mg/day) and hydrochlorothiazide 25 mg/day (force-titrated to 50 mg/day) in untreated hypertensive patients. The main outcome, 24-hour ambulatory blood pressure (BP) monitoring, was assessed at baseline and week 8, along with standard office BP readings every 2 weeks. Thirty patients completed the first active treatment period, whereas 24 patients completed both. An order–drug–time interaction was observed with chlorthalidone; therefore, data from only the first active treatment period was considered. Week 8 ambulatory BPs indicated a greater reduction from baseline in systolic BP with chlorthalidone 25 mg/day compared with hydrochlorothiazide 50 mg/day (24-hour mean = –12.4±1.8 mm Hg versus –7.4±1.7 mm Hg; P=0.054; nighttime mean = –13.5±1.9 mm Hg versus –6.4±1.8 mm Hg; P=0.009). Office systolic BP reduction was lower at week 2 for chlorthalidone 12.5 mg/day versus hydrochlorothiazide 25 mg/day (–15.7±2.2 mm Hg versus –4.5±2.1 mm Hg; P=0.001); however, by week 8, reductions were statistically similar (–17.1±3.7 versus –10.8±3.5; P=0.84). Within recommended doses, chlorthalidone is more effective in lowering systolic BPs than hydrochlorothiazide, as evidenced by 24-hour ambulatory BPs. These differences were not apparent with office BP measurements.
Key Words: diuretics • blood pressure monitoring, ambulatory • antihypertensive agents • hypertension, essential • antihypertensive therapy
Related Article:
Hypertension 2006 47: 321-322.
This article has been cited by other articles:
 |
|
 |
|
  M. Moser and P. U. Feig Fifty Years of Thiazide Diuretic Therapy for Hypertension Arch Intern Med, November 9, 2009; 169(20): 1851 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Kaplan The Choice of Thiazide Diuretics: Why Chlorthalidone May Replace Hydrochlorothiazide Hypertension, November 1, 2009; 54(5): 951 - 953. [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. O'Keefe, M. D. Carter, and C. J. Lavie Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach Mayo Clin. Proc., August 1, 2009; 84(8): 741 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Wright Jr, J. L. Probstfield, W. C. Cushman, S. L. Pressel, J. A. Cutler, B. R. Davis, P. T. Einhorn, M. Rahman, P. K. Whelton, C. E. Ford, et al. ALLHAT Findings Revisited in the Context of Subsequent Analyses, Other Trials, and Meta-analyses Arch Intern Med, May 11, 2009; 169(9): 832 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. V. Menon, D. Arbique, Z. Wang, B. Adams-Huet, R. J. Auchus, and W. Vongpatanasin Differential Effects of Chlorthalidone Versus Spironolactone on Muscle Sympathetic Nerve Activity in Hypertensive Patients J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1361 - 1366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Messerli and S. Bangalore Antihypertensive Efficacy of Aliskiren: Is Hydrochlorothiazide an Appropriate Benchmark? Circulation, January 27, 2009; 119(3): 371 - 373. [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Chobanian Does It Matter How Hypertension Is Controlled? N. Engl. J. Med., December 4, 2008; 359(23): 2485 - 2488. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Sarafidis and G. L. Bakris Resistant Hypertension An Overview of Evaluation and Treatment. J. Am. Coll. Cardiol., November 25, 2008; 52(22): 1749 - 1757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Calhoun, D. Jones, S. Textor, D. C. Goff, T. P. Murphy, R. D. Toto, A. White, W. C. Cushman, W. White, D. Sica, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Circulation, June 24, 2008; 117(25): e510 - e526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Calhoun, D. Jones, S. Textor, D. C. Goff, T. P. Murphy, R. D. Toto, A. White, W. C. Cushman, W. White, D. Sica, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension, June 1, 2008; 51(6): 1403 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cutler and B. R. Davis Thiazide-Type Diuretics and {beta}-Adrenergic Blockers as First-Line Drug Treatments for Hypertension Circulation, May 20, 2008; 117(20): 2691 - 2705. [Full Text] [PDF]
|
|
|
|
|
|
B. Williams The Year in Hypertension J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1803 - 1817. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Sica Chlorthalidone: Has It Always Been the Best Thiazide-Type Diuretic? Hypertension, March 1, 2006; 47(3): 321 - 322. [Full Text] [PDF]
|
|